.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Covington
McKinsey
Express Scripts
Accenture
Moodys
US Army
Colorcon
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,566,445

« Back to Dashboard

Which drugs does patent 7,566,445 protect, and when does it expire?


Patent 7,566,445 protects PROAIR HFA and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 7,566,445

Title:Medicinal aerosols and methods of delivery thereof
Abstract:This invention provides a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, wherein the aerosol formulation is free of surfactant. This invention also provides a medicinal aerosol formulation, including one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent. In addition, this invention provides a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant, and 6% to 25% of a polar co-solvent, which is substantially free of surfactant, wherein the propellant comprises a fluorocarbon.
Inventor(s): Millar; Fiona Catherine (Waterford, IE)
Assignee: Norton Healthcare Limited (GB)
Application Number:08/999,752
Patent Claim Types:
see list of patent claims
Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Teva Branded PharmPROAIR HFAalbuterol sulfateAEROSOL, METERED;INHALATION021457-001Oct 29, 2004BXRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,566,445

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9616237.5Aug 01, 1996

Non-Orange Book Patents for Patent: 7,566,445

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,834,849Medicinal aerosols and methods of delivery thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,566,445

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway325491► Subscribe
Norway990454► Subscribe
Japan2011173910► Subscribe
Japan4794701► Subscribe
Japan2000515536► Subscribe
United Kingdom9616237► Subscribe
Spain2175413► Subscribe
European Patent Office0918507► Subscribe
Denmark0918507► Subscribe
Germany69711637► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Moodys
McKesson
Argus Health
Merck
Chinese Patent Office
Cipla
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot